Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VICL

Vical (VICL) Stock Price, News & Analysis

Vical logo

About Vical Stock (NASDAQ:VICL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.68
$3.15
52-Week Range
N/A
Volume
35,024 shs
Average Volume
1.44 million shs
Market Capitalization
$21.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive VICL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vical and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VICL Stock News Headlines

Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
See More Headlines

VICL Stock Analysis - Frequently Asked Questions

Vical Incorporated (NASDAQ:VICL) announced its quarterly earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The biotechnology company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.04 million. Vical had a negative trailing twelve-month return on equity of 29.46% and a negative net margin of 1,002.10%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vical investors own include Caladrius Biosciences (CLBS), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), CTI BioPharma (CTIC) and Idera Pharmaceuticals (IDRA).

Company Calendar

Last Earnings
2/19/2019
Today
9/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VICL
CIK
819050
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.81)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.25 million
Net Margins
-1,002.10%
Pretax Margin
N/A
Return on Equity
-29.46%
Return on Assets
-27.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
36.84
Quick Ratio
36.84

Sales & Book Value

Annual Sales
$1.62 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.82 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
22,840,000
Free Float
N/A
Market Cap
$21.01 million
Optionable
Not Optionable
Beta
0.32
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:VICL) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners